ClinicalTrials.gg

Program

JNJ-86974680

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms, led by Johnson & Johnson.

Furthest: phase 1, since Oct 31, 20232 company-led studies, 2 open or runningNext primary completion: Jan 7, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson22 open or runningphase 1since Oct 31, 2023Oct 31, 2023Jan 7, 2027phase 1 · NCT07319871

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 31, 2023First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06116786 · 67 enrolled · United States, Germany, South Korea and more
  2. Dec 22, 2025Phase 1 study in Prostatic NeoplasmsNCT07319871 · 40 planned · United States, United Kingdom

Ahead

  1. Jan 7, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT07319871
  2. Apr 14, 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT06116786

TargetBeta

ADORA2A →read by rule
“An immune checkpoint inhibitor and antagonist of the adenosine A2A receptor (A2AR; ADORA2A), ”NCIt, by rule

Other programs on ADORA2A

ProgramCompanyFurthest phaseStudies
CaffeineruleBoehringer Ingelheimphase 430

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07319871Prostatic Neoplasms · United States, United Kingdom1RecruitingJan 7, 202740
NCT06116786Carcinoma, Non-Small-Cell Lung · United States, Germany, South Korea and more1Active, not recruitingApr 14, 202767

How it is read

Names in the registry

  • “JNJ-86974680”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.